Kruppel-like factor 10 (KLF10) as a biomarker of endothelial progenitor cell dysfunction

Patent metadata

Field	Value
Publication number	US-9500658-B2
Application number	US-201214003852-A
Country	US
Kind code	B2
Filing date	Mar 9, 2012
Priority date	Mar 9, 2011
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

The use of Kruppel-like Factor (KLF10) as a diagnostic and prognostic tool for peripheral artery disease and other disease conditions associated with reduced angiogenesis or endothelial progenitor cell dysfunction such as diabetes and stent thrombosis.

First claim

What is claimed is:

1. A method of diagnosing and treating peripheral artery disease (PAD) in a subject, the method comprising:
isolating CD34 + /VEGFR2 + pro-angiogenic peripheral blood cells from the subject by flow cytometry;
performing an assay to determine a level of Krüppel-like Factor (KLF 10) expression in a sample comprising the peripheral blood cells;
comparing the level of KLF10 in the sample to a reference level of KLF 10;
identifying a subject who has a level of KLF 10 in the sample below the reference level as having PAD; and
administering a treatment for PAD to the identified subject who has a level of KLF10 in the sample that is below the reference level, wherein the treatment comprises a lipid-lowering agent.

2. A method of diagnosing and treating diabetic vasculopathy in a subject with diabetes, the method comprising:
isolating CD34 + /VEGFR2 + pro-angiogenic peripheral blood cells from the subject by flow cytometry;
performing an assay to determine a level of Krüppel-like Factor (KLF10) expression in a sample comprising the peripheral blood cells;
comparing the level of KLF10 in the sample to a reference level of KLF10;
identifying a subject who has a level of KLF10 in the sample below the reference level as having diabetic vasculopathy; and
administering a treatment for diabetic vasculopathy to the identified subject who has a level of KLF10 in the sample that is below the reference level, wherein the treatment comprises an angiotensin-converting enzyme (ACE) inhibitor.

3. The method of claim 2 , wherein the subject has type 2 diabetes.

4. The method of claim 1 , further comprising
performing an assay to determine a level of KLF10 expression in a subsequent sample comprising CD34 + /VEGFR2 + pro-angiogenic peripheral blood cells from the subject; and
comparing the level of KLF10 in the subsequent sample to the level of KLF10 in the earlier sample;
wherein an increase in a level of KLF10 in the subsequent sample as compared to the earlier sample indicates that the treatment is effective.

5. The method of claim 2 , further comprising
performing an assay to determine a level of KLF10 expression in a subsequent sample comprising CD34 + /VEGFR2 + pro-angiogenic peripheral blood cells from the subject; and
comparing the level of KLF10 in the subsequent sample to the level of KLF10 in the earlier sample;
wherein an increase in a level of KLF10 in the subsequent sample as compared to the earlier sample indicates that the treatment is effective.

6. The method of claim 1 , wherein the level of KLF10 expression in the sample is determined by quantitative PCR, flow cytometry, or quantitative immunoassay.

7. The method of claim 2 , wherein the level of KLF10 expression in the sample is determined by quantitative PCR, flow cytometry, or quantitative immunoassay.

8. A method of diagnosing and treating stent thrombosis in a subject with a stent, the method comprising:
isolating CD34 + /VEGFR2 + pro-angiogenic peripheral blood cells from the subject by flow cytometry;
performing an assay to determine a level of Krüppel-like Factor (KLF10) expression in a sample comprising the peripheral blood cells;
comparing the level of KLF10 in the sample to a reference level of KLF10;
identifying a subject who has a level of KLF10 in the sample below the reference level as having stent thrombosis; and
administering a treatment for stent thrombosis to the identified subject who has a level of KLF10 in the sample that is below the reference level, wherein the treatment comprises dual anti-platelet therapy.

9. The method of claim 8 , further comprising
performing an assay to determine a level of KLF10 expression in a subsequent sample comprising CD34 + /VEGFR2 + pro-angiogenic peripheral blood cells from the subject; and
comparing the level of KLF10 in the subsequent sample to the level of KLF10 in the earlier sample;
wherein an increase in a level of KLF10 in the subsequent sample as compared to the earlier sample indicates that the treatment is effective.

10. The method of claim 8 , wherein the level of KLF10 expression in the sample is determined by quantitative PCR, flow cytometry, or quantitative immunoassay.

11. The method of claim 1 , wherein the lipid-lowering agent is a statin, fibrate, or niacin.

12. A method of diagnosing and treating stent thrombosis in a subject with a stent, the method comprising:
isolating CD34 + /VEGFR2 + pro-angiogenic peripheral blood cells from the subject by flow cytometry;
performing an assay to determine a level of Krüppel-like Factor (KLF10) expression in a sample comprising the peripheral blood cells;
comparing the level of KLF10 in the sample to a reference level of KLF10;
identifying a subject who has a level of KLF10 in the sample below the reference level as having stent thrombosis; and
administering a treatment for stent thrombosis to the identified subject who has a level of KLF10 in the sample that is below the reference level, wherein the treatment comprises anti-coagulation therapy.

13. The method of claim 12 , further comprising
performing an assay to determine a level of KLF10 expression in a subsequent sample comprising CD34 + /VEGFR2 + pro-angiogenic peripheral blood cells from the subject; and
comparing the level of KLF10 in the subsequent sample to the level of KLF10 in the earlier sample;
wherein an increase in a level of KLF10 in the subsequent sample as compared to the earlier sample indicates that the treatment is effective.

14. The method of claim 12 , wherein the level of KLF10 expression in the sample is determined by quantitative PCR, flow cytometry, or quantitative immunoassay.

Assignees

• Feinberg Mark W
• Wara Akm Khyrul
• Brigham & Womens Hospital Inc

Inventors

• Feinberg Mark W
• Wara Akm Khyrul

Classifications

• G01N2800/32

  Cardiovascular disorders · CPC title

• G01N2800/50

  Determining the risk of developing a disease · CPC title

• G01N33/6893 Primary

  related to diseases not provided for elsewhere · CPC title

• G01N33/6872 Primary

  Intracellular protein regulatory factors and their receptors, e.g. including ion channels · CPC title

• G01N2333/4703

  Regulators; Modulating activity · CPC title